Abstract: To discuss the clinical efficacy,immunological consequences and adverse effects of anti-CD20 monoclonal antibody in systemic lupus erythematosus .A total of nearly 100 patients have been reported,and about 80% of them achieved marked reduction in global disease activity,clinical remission in lupus nephritis.Anti-CD20 monoclonal antibody was well tolerated in 90% of the patients,though10% of them had hypersensitivity reactions and 4 patients had severe infection.